US Newborn Screening System Guidelines II: Follow-up of Children, Diagnosis, Management, and Evaluation Statement of the Council of Regional Networks for Genetic Services (CORN)Kenneth A. Pass, Louis J. Elsas, Peter A. Lane et al.|The Journal of Pediatrics|2000Cited by 159
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imigluceraseAri Zimran, Gregory A. Grabowski, Gregory M. Pastores et al.|American Journal of Hematology|2012Cited by 62
Heparin cofactor II–thrombin complex: A biomarker of MPS diseaseDerrick R. Randall, L. Clarke, Karen E. Colobong et al.|Molecular Genetics and Metabolism|2008Cited by 62
Creating genetics-based infusion centers: a case study of two modelsDawn J. Laney, Paul M. Fernhoff, Amy White et al.|Genetics in Medicine|2008Cited by 2
482 Safety and Efficacy of Velaglucerase Alfa in Gaucher Disease Type 1 Patients Previously Treated with ImigluceraseGregory A. Grabowski, E. Crombez, GM Pastores et al.|Pediatric Research|2010Cited by 0